xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22741 by Stanford University, Wiley Online Library on [01/07/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

455

Orlandi et al.

of medical management in CRSwNP regardless of in vitro allergy test results.

SPT No Presence of allergy did not affect polyp size, symptoms, CT

opacification, or disease recurrence.

biomarker analysis (IgE,

IgA, IL-5, IL-9, ECP, EDN) in blood, and nasal secretions.

CRSwNP. PAR and tobacco associated with NP.

Invitro No No difference in symptoms at presentation or after 1 year

Study Year LOE Study Design Study Groups Clinical Endpoint Houser 1381 2008 4 Retrospective case control Surgical CRSwNP pts Rate of atopy by In vitro /IDT Invitro /IDT Yes Increase in PAR among Polyp size Method Surgical CRSsNP patients

Concordance of SPT and

Association between Allergy and CRSwNP Conclusions

Allergy

Testing

Total eosinophil count

biomarkers (IgE, IgA, IL-5, IL-9,

ECP, EDN) in

blood and nasal secretions

Bonfils 1389 2006 4 Prospective case series CRSwNP Nasal obstruction Anterior and posterior

rhinorrhea

CTscore

Serum total IgE

Symptom score Recurrence

Mortuaire 1386 2018 5 Prospective case series CRSwNP Rate of atopy by SPT Rate of positive

Facial pain

Loss of sense of smell

CRSwNPand allergy

CRSwNP without allergy

Erbek 1388 2007 4 Retrospective case series

TABLE X-4 (Continued)